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iThe ﬁrst successful human bone marrow transplan-
ation for an infant with X-linked severe combined im-
une deﬁciency (X-SCID) in 1968 initiated the era of
ffective treatment for the congenital immune deﬁcien-
ies [1,2]. Over the ensuing 4 decades, transplantation of
LA-identical hematopoietic stem cells from bone mar-
ow or peripheral blood has become the standard of care
or the severe immune deﬁciencies (severe combined
mmune deﬁciency [SCID], Wiskott-Aldrich syndrome,
-linked hyperimmunoglobulin M, and X-linked lym-
hoproliferative syndrome), and long-term cure rates of
95% have been reported [3-7]. However, not every
ransplantation is from an HLA-matched donor. The
esults of using matched unrelated or haploidentical (pa-
ental) transplants are not as successful. In up to approx-
mately 50% of cases, these transplantations are compli-
ated by suboptimal immune reconstitution and serious
dverse events (SAEs), including graft-versus-host dis-
ase (GVHD) and life-threatening graft failure. Graft
ailure occurs particularly if transplantation is performed
ater in a patient’s clinical course, frequently as a result of
nderlying infection [3,4]. Because of these limitations,
he alternative approach of gene therapy was proposed.
he rationale for gene therapy is compelling: with gene-
odiﬁed autologous stem cells, the need for an alloge-
eic donor and the concomitant potentially severe con-
equences of GVHD or graft failure should be
revented. The underlying basis for gene therapy for
evere immune deﬁciencies is that selective survival of
ature lymphocytes derived from a few gene-modiﬁed
rimitive progenitors should lead to immunologic re-
onstitution.
The ﬁrst gene therapy clinical trials were per-
ormed in patients with the rare congenital disease
denosine deaminase (ADA)–deﬁcient SCID (ADA-
CID) [8-16]. ADA-SCID is caused by mutations in g
72he ADA gene and, if untreated, is generally fatal
ithin the ﬁrst 2 years of life. ADA-SCID is currently
reated primarily by bone marrow transplantation or
egylated bovine ADA (PEG-ADA) enzyme-replace-
ent therapy (ERT). The initial ADA-SCID gene
herapy trials in the 1990s focused on gene modiﬁca-
ion of autologous, mature lymphocytes from periph-
ral blood [8,10,13-15]. Additional trials used CD34
rogenitor cells from bone marrow [11,17] and um-
ilical cord blood [9,12,16]. Along with the gene ther-
peutic intervention, patients were maintained on
oncurrent PEG-ADA ERT. Attempts to discontinue
RT after gene transfer were generally unsuccessful
r, at best, marginally successful [8,12,15]. In 1 case,
ong-term oligoclonal marking of approximately 10%
f peripheral lymphocytes from transduced CD34
ells was seen, but this level was not sufﬁcient for
mmune protection [16]. The results of these studies
howed that low levels of gene marking were univer-
ally seen and that long-term cure was not. Although
neffective, the gene transfer methods used were safe
ver the period of patient follow-up.
In the seminal gene therapy study of Fischer and
olleagues in Paris, X-SCID was the ﬁrst human disease
o demonstrate clinical “cure” by gene therapy [18,19].
-SCID is characterized by defective signal transduction
hrough the common gamma chain (c) receptor (via the
ytokines interleukin 2, 4, 7, 9, 15, and 21) caused by
utations in the c gene. Clinically, the immune deﬁ-
iency results from inadequate production of T and
atural killer lymphocytes and defective B-cell function.
he high-level expression of the common c receptor
ransgene after CD34 cell transduction by a retroviral
ector restored responsiveness to cytokines and resulted
n differentiation and proliferation of transduced pro-
enitors into all the mature lymphoid lineages [18,19].
T
t
(
i
p
s
m
t
T
s
c
“
f
c
t
i
r
t
l
j
t
t
a
w
b
i
c
w
e
c
b
(
t
t
n
j
t
i
o
a
l
i
q
l
p
s
s
h
i
t
k
t
g
U
I
i
t
t
s
o
e
o
t
S
s
t
1
o
t
b
i
t
s
m
(
g
t
t
s
S
a
s
o
i
4
d
s
l
S
2
N
I
d
i
A
p
p
p
b
A
D
w
d
z
w
d
3
Gene Therapy for Immune Deficiencies
Bhe results were compelling—immune reconstitution of
he initial 9 of 10 treated children in this study [19]
unpublished ﬁndings were reported at the 2004 Amer-
can Society of Gene Therapy annual meeting). The
harmacokinetics of reconstitution showed brisk expan-
ion of the deﬁcient T and natural killer lineages; B-cell
arking remained low, however, when compared with
he other lineages. The clinical beneﬁts were dramatic.
he treated children demonstrated immune protection,
ome for more than 5 years as of this time. One young
hild whose therapy failed in this study presumably
lost” his infused, transduced CD34 from splenectomy
or splenic enlargement, probably because of prior Ba-
ille Calmette Guerin administration [19]. Older pa-
ients have also not shown beneﬁt, perhaps because of
nadequate thymic function [20].
Unfortunately, in 2002 the French investigators
eported that 2 of the treated children who had ini-
ially reconstituted immunity subsequently developed
ymphoproliferative leukemia-like syndromes (sub-
ects 4 and 5 of the trial) [21-24]. A recently developed
echnique to recover integrated vector sequences and
he ﬂanking cellular DNA sequences, called linear
mpliﬁcation–mediated polymerase chain reaction,
as performed on genomic DNA from peripheral
lood leukocytes. For the time points shortly after cell
nfusion, numerous proviral integrants presumably
oming from several different transduced progenitors
ere identiﬁable in each child (multiclonality). How-
ver, over time, the initial multiclonal population of
ells with vectors at many different sites was replaced
y a predominantly single, uniform population
monoclonality) of rapidly proliferating lymphocytes.
Unexpectedly, the abnormal monoclonal prolifera-
ion in subjects 4 and 5 involved a lymphocyte popula-
ion with a single retroviral integration site that was
early identical in each case. The insertional event
udged to be oncogenic in these 2 patients was in or near
he LIM domain only (LMO)-2 proto-oncogene, result-
ng in its transactivation and overexpression. This proto-
ncogene not only is active in normal T-cell differenti-
tion, but is also implicated in some cases of acute T-cell
ymphocytic leukemia [25,26]. A third case of leukemia
n an initially immune reconstituted child was subse-
uently reported in January 2005 (subject 10) [27]. Mo-
ecular characterization of the leukemia has not been
ublished as of this writing, although an initial report
uggested that the cells had vector-integrated at several
ites, including LMO-2. Each of the 3 affected children
ad the onset of leukemia at 30 to 36 months after
nfusion of gene-modiﬁed progenitors. Regrettably,
he ﬁrst child to develop gene therapy–related leu-
emia died.
The primary event for the oncogenic outcome seems
o be insertional transactivation of the LMO-2 onco-
ene, under the inﬂuence of the strong enhancer in the
3 region of the retroviral vector long terminal repeat. o
B&MTntegrating the common c-receptor gene under the
nﬂuence of a strong viral enhancer near an oncogene,
hus resulting in oncogene transactivation, may essen-
ially be the same as providing a “double hit” with re-
pect to the neoplastic process. That is, the combination
f a constitutively active gene controlling cellular prolif-
ration (c) and the transactivation of a cellular proto-
ncogene (LMO-2) provides a greater survival advan-
age for cells.
The ﬁrst 2 cases of lymphoproliferation in the X-
CID gene therapy trial suggested that the risks of in-
ertional oncogenesis were increased by high doses of
ransduced cells (subjects 4 and 5 received 3.8 and 2.8
07/kg transduced CD34 cells, respectively) and an age
f 6 months at study entry. Because the risk of inser-
ional oncogenesis is probably proportional to the num-
er of proviral integrants, the more transduced cells
nfused, the greater the risk of oncogenesis. However,
he third child to develop leukemia received a relatively
maller cell dose (1.1  107) and at study entry was 6
onths of age [27]. Although the issues of cellular dose
and the resulting numbers of different proviral inte-
rants) and of patient and/or cell age may contribute to
he leukemias, their roles are not currently known. Even
hough vector-mediated insertional oncogenesis was de-
cribed in the ﬁrst 2 children with SAEs from the X-
CID trial (and probably the third recently reported)
nd in mice [28,29], the collective results of numerous
tudies in both animals and humans suggest that the
verall risk of oncogenesis with retroviral vectors per se
s low [30]. In this regard, the results of gene therapy in
X-SCID patients by Thrasher and colleagues in Lon-
on, England, recapitulate the success of the French
tudy through 27 months of the longest patient fol-
ow-up without the SAE of leukemia [20,31].
Our clinical trial (unpublished results) for ADA-
CID using retroviral vectors that target CD34 cells (at
sites: the Children’s Hospital Los Angeles and the
ational Human Genome Research Institute, National
nstitutes of Health) without PEG-ADA enzyme with-
rawal and without marrow cytoreduction has resulted
n levels of gene marking insufﬁcient to withdraw PEG-
DA. The concomitant administration of PEG-ADA
robably diminished any selective survival of the lym-
hocytes derived from the engrafted, transduced CD34
rogenitors [17].
In contrast, over the past several years, results have
een unfolding of a clinical trial of gene therapy for
DA-SCID in Milan, Italy, under the direction of
r. Claudio Bordignon and colleagues. The Milan trial
as designed for children to receive autologous, trans-
uced CD34 progenitor cells without PEG-ADA en-
yme replacement after bone marrow cytoreduction
ith busulfan (4 mg/kg), a chemotherapeutic agent that
ecreases the hematopoietic stem cell population [32-
4]. In the posttreatment period, the children remained
ff PEG-ADA and were kept in protective isolation.
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9ngraftment of transduced progenitors, indicated by a
evel of approximately 10% of peripheral blood myeloid
ells with the ADA transgene, resulted in approximately
00% gene-modiﬁed peripheral lymphocytes, thus sug-
esting selective survival of these cells. The initial report
f 2 treated children demonstrated that each of them
econstituted immunity [35]. After this initial report,
ata from an additional 4 subjects were presented [36]
American Society of Gene Therapy annual meetings of
004 and 2005 and the US Food and Drug Administra-
ion’s Biological Response Modiﬁers Advisory Commit-
ee meeting, March 2005) with the exciting news that
ach subject reconstituted immunity sufﬁciently to
aintain them off PEG-ADA. Recently, a similar result
as seen with melphalan conditioning in a child with
DA-SCID, without PEG-ADA replacement, treated in
ondon, England.
Despite the similarities between the clinical manifes-
ations of X-SCID and of ADA-SCID, the underlying
enetic mutations, molecular mechanisms, and patho-
enesis of disease are different. Whereas X-SCID is
haracterized by a lack of production (lack of prolifera-
ion) of the different lymphoid lineages, thus resulting in
ew circulating lymphocytes, ADA-SCID is character-
zed by lymphocyte intoxication by adenosine metabo-
ites, thus resulting in cell toxicity and death. Placing a
ell receptor for signal transduction on a lymphocyte of
n X-SCID patient by gene therapy results in cellular
roliferation; expressing the ADA enzyme in a lympho-
yte from an ADA-SCID patient by gene therapy results
n detoxiﬁcation of the cell, thereby allowing it to survive
nd restore immunity.
The kinetics of immune reconstitution in X-SCID
nd ADA-SCID patients treated by gene therapy seem
ifferent. For X-SCID patients, the time interval to
chieve normal levels of circulating lymphocytes after
ene therapy was relatively short (60-90 days after treat-
ent). For the ADA-SCID patients, circulating lympho-
yte counts reached maximal levels at 3 to 6 months, or
onger, after gene therapy. The lymphocyte counts in
he treated ADA patients were actually lower than nor-
al but resulted in protective immunity. It is not known
hether these kinetic differences of immunologic recon-
titution when comparing X-SCID and ADA-SCID
ene therapy patients are due to different numbers of
ransduced progenitors or to a different intrinsic rate of
roliferation of gene-modiﬁed lymphocytes. Although
he rapid immune reconstitution in treated X-SCID ini-
ially seemed to be an advantage, the selective survival
nd proliferation of cells with oncogenic potential un-
ortunately led to long-term adverse consequences in
everal patients.
In summary, the early results of gene therapy for
ongenital immune deﬁciencies in young children with
-SCID showed an initial rate of immune reconstitution
f 13 of 14 subjects (Paris and London data); 3 of the
nitial reconstitutions were complicated by vector-re- [
74ated leukemia. This SAE rate of gene therapy ultimately
eeds to be compared with that of the incidence of graft
ailure and severe GVHD in studies of transplantation of
-SCID with haploidentical and matched unrelated
ransplants. The studies of ADA-SCID that combined
EG-ADA ERT withdrawal and bone marrow cytore-
uction with busulfan demonstrated excellent immune
econstitution (7 out of 7 children: 6 in Milan and 1 in
ondon) and, to date, no reports of SAEs. Further clin-
cal studies and data accrual for both types of SCID will
elp to determine whether the clinical results of gene
herapy are better or worse than those of transplantation,
EG-ADA ERT, or both.
There are several considerations for improving the
afety of the vector in the X-linked SCID studies. A
entiviral vector cloned from human immunodeﬁciency
irus (HIV)–1 may be safer than a retroviral vector if
entiviral integration is less directed to the 5= region of
ctively replicating genes, as has been described for ret-
oviral vector integrations [37-39]. The choice of pro-
oter may be optimized. For years, onemajor deﬁciency
n gene therapy was inadequate expression; now the
xpression provided by viral-enhancer elements is strong
nough to transactivate nearby oncogenes. With this in
ind, the strong enhancers may be deleted or decreased
n activity, the promoter may be replaced with a weaker,
onstitutive promoter, or chromosomal “insulator” se-
uences may be added to the vector. Potentially, the
ndogenous c gene promoter would allow for control-
able, regulated levels of c. These approaches need to be
ested to see whether sufﬁcient levels of lymphocyte
DA (ADA-SCID) or surface c (X-SCID) would be
xpressed for immunologic reconstitution.
Although gene therapy studies of the relatively rare
mmune deﬁciencies X-SCID and ADA-SCID have
emonstrated success, clinical studies of other hemato-
ogic diseases have developed more slowly. The hemo-
lobinopathies, including the thalassemias and sickle cell
nemia, are potential gene therapy targets that hold the
romise of effectively treating large groups of affected
atients [40]. Because vector stability has been problem-
tic with retroviral constructs, the use of lentiviral vec-
ors for these hemoglobinopathies may be more feasible
41,42]. Metabolic storage diseases such as Gaucher and
urler disease are other hematologic diseases for which
ene therapy has been proposed [43,44]. Whether im-
unologic rejection of newly expressed transgene pro-
eins will occur in the immune-competent patients with
hese diseases is not known. Another potential target for
ematopoietic progenitor gene therapy is that of chronic
nfectious disease. An example is HIV-1, for which
ighly active antiretroviral therapy offers prolongation
f life but not cure. The rationale for HIV-1 gene ther-
py is that an inhibitory gene may confer protection to
ature lymphocytes and promote a survival advantage to
elp rebuild immunity with these gene-modiﬁed cells
45]. Several different approaches have been proposed,
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Gene Therapy for Immune Deficiencies
Bncluding decoy molecules, ribozymes, antisense, small
nterfering RNA, surface fusion proteins, and disruption
f the REV-RRE axis [46-57]. One study recently dem-
nstrated a long-term survival advantage of mature lym-
hocytes derived from gene-modiﬁed bone marrow pro-
enitors in a child, providing a proof of principle of
ematopoietic progenitor cell gene transfer for HIV-1
58]. To date, however, low levels of gene marking in
hese types of studies have hampered clinical progress.
The rightful place for hematopoietic stem cell gene
herapy in clinical practice remains to be seen, but the
nitial results in the inherited immune deﬁciencies X-
CID and ADA-SCID unequivocally demonstrate its
tility. After the immune reconstitution of gene therapy,
ong-term follow-up of patients is crucial to understand
he permanence of treatment and also its overall safety.
fter many years of failed attempts, the gene therapy
eld now has several dramatic successes to claim, as well
s some SAEs. It will be interesting to follow the appli-
ation of gene therapy methods to blood cell disorders
ther than the immune deﬁciencies. Extensive follow-up
f additional enrolled patients will tell whether gene
herapy for immune deﬁciencies and other diseases be-
omes merely one of several therapeutic alternatives or
ltimately develops into the standard of care for patients
ith these life-threatening hematologic diseases.
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